Dojolvi

Dojolvi Uses, Dosage, Side Effects, Food Interaction and all others data.

Dojolvi is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly. Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin.

Dojolvi was granted FDA approval on 30 June 2020.

Dojolvi is a source of medium chain fatty acids for patients with lc-FAODs. It has a moderate duration of action and a wide therapeutic window. Patients should be counselled regarding the risk of feeding tube dysfunction and intestinal malabsorption due to pancreatic insufficiency.

Table Of contents

• Dojolvi
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Dojolvi
Availability	Prescription only
Generic	Triheptanoin
Triheptanoin Other Names	Glycerol triheptanoate, Glyceryl triheptanoate, Trienanthoin, Triheptanoic glyceride, Triheptanoin, Triheptylin, Trioenanthoin
Related Drugs	Dojolvi
Weight	100%,
Type	Oral liquid
Formula	C24H44O6
Weight	Average: 428.61 Monoisotopic: 428.313789137
Protein binding	Triheptanoin is approximately 80% protein bound in plasma, likely serum albumin.
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	United States,
Last Updated:	September 19, 2023 at 7:00 am

Uses

Dojolvi is triheptanoin is a medium chain triglyceride indicated to provide calories and fatty acids to treat long chain fatty acid oxidation disorders.

Dojolvi is a medium chain triglyceride indicated to provide calories and fatty acids to treat long chain fatty acid oxidation disorders (lc-FAODs).

Dojolvi is also used to associated treatment for these conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

How Dojolvi works

Dojolvi is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with lc-FAODs treated with triheptanoin experienced improvements in hypoglycemia, cardiomyopathy, and rhabdomyolysis.

Food Interaction

• Take with food. Take triheptanoin with food, liquid, or formula.

Elimination Route

A single 0.3 g/kg dose of triheptanoin reaches a C_max of 178.9 µmol/L, with a T_max 0.5 h, and an AUC of 336.5 µmol*h/L. A single 0.4 g/kg dose of triheptanoin reaches a C_max of 259.1 µmol/L, with a T_max 0.8 h, and an AUC of 569.1 µmol*h/L.

Half Life

Due to multiple peak concentrations of the heptanoate metabolite, the half life of triheptanoin could not be determined.

Clearance

A single dose of 0.3 g/kg results in a mean apparent clearance of 6.05 L/h/kg for heptanoate. A single dose of 0.4 g/kg results in a mean apparent clearance of 4.31 L/h/kg for heptanoate.

Elimination Route

Dojolvi is minimally eliminated in the urine.

Innovators Monograph

You find simplified version here Dojolvi